This competitive landscape analysis was generated using AI-powered research workflows in Eureka LS, which integrates patent data, literature, and molecular insights into a structured report in minutes. Executive Summary The VEGF pathway is one of the most heavily validated drug targets in medicine, with 550+ drugs in the full development rollup across VEGF and VEGFR family members, 64 approved agents, and 725+ active Phase 3 trials as of 2025–2026. VEGF The landscape is bifurcated by therapeutic area: oncology (dominated by bevacizumab/biosimilars and VEGFR TKIs) and ophthalmology (dominated by anti-VEGF-A biologics for AMD, DME, and RVO). The competitive dynamic is shifting…
Author: Eureka LS
This competitive landscape analysis was generated using AI-powered research workflows in Eureka LS, which integrates patent data, literature, and molecular insights into a structured report in minutes. Executive Summary The RET inhibitor arena has undergone a decisive structural shift since 2020: the field moved from multi-kinase inhibitors (vandetanib, cabozantinib) with poor selectivity and broad toxicity to a second generation of highly selective RET inhibitors validated by two global approvals. Eli Lilly/Loxo Oncology’s selpercatinib (Retevmo) and Blueprint Medicines’ pralsetinib (Gavreto) now define the global standard of care for RET fusion-positive NSCLC and RET-mutant medullary thyroid cancer. The patent foundation is dominated…
This competitive landscape analysis was generated using AI-powered research workflows in Eureka LS, which integrates patent data, literature, and molecular insights into a structured report in minutes. Executive Summary SHP2 (PTPN11) has emerged as one of the most strategically important oncology targets of the 2020s, serving as a critical node in the RAS/MAPK signaling pathway and a validated combination partner for KRAS inhibitors. The database records 126 drugs and 127 clinical trials associated with SHP2, with the overwhelming majority being allosteric small-molecule inhibitors. The competitive arena is moderately concentrated at the clinical frontier — one Phase 3 asset (sitneprotafib/JAB-3312, Jacobio…
This competitive landscape analysis was generated using AI-powered research workflows in Eureka LS, which integrates patent data, literature, and molecular insights into a structured report in minutes. Executive Summary The bispecific monoclonal antibody (BsMAb) sector has transitioned from a niche modality into one of the most active areas of biopharmaceutical development. As of 2025–2026, more than 15 distinct bispecific antibodies have received regulatory approval globally, spanning oncology, hematology, ophthalmology, and hemophilia. The patent landscape contains over 23,500 active filings globally, with annual applications peaking at ~2,640 in 2022 and remaining above 2,200 in 2024. The competitive arena is dominated by…
This competitive landscape analysis was generated using AI-powered research workflows in Eureka LS, which integrates patent data, literature, and molecular insights into a structured report in minutes. Abstract KRAS G12C (GTPase KRas, UniProt P01116) KRAS is a constitutively activating point mutation found in ~13% of NSCLC, ~3–4% of CRC, and ~1–2% of PDAC. Once considered undruggable due to the absence of a classical binding pocket, the discovery of the switch-II pocket (S-IIP) enabled covalent inhibitors to lock the protein in its inactive GDP-bound state. This report covers the full competitive landscape: approved drugs, late-stage pipeline, emerging modalities, deal activity, and…
This competitive landscape analysis was generated using AI-powered research workflows in Eureka LS, which integrates patent data, literature, and molecular insights into a structured report in minutes. Executive Summary The mRNA technology arena is a high-concentration, fast-growing sector with two dominant Tier 1 Western players (Moderna, BioNTech) commanding the largest patent portfolios and the only approved products, while a Tier 2 challenger cohort (Translate Bio/Sanofi, CureVac, Arcturus) competes on specialized delivery and therapeutic routes. A structurally distinct Chinese cluster — led by Suzhou Abogen, Immorna, and Jitai Pharmaceutical — has mounted a credible international IP push since 2021 and now…
This competitive landscape analysis was generated using AI-powered research workflows in Eureka LS, which integrates patent data, literature, and molecular insights into a structured report in minutes. Executive Summary The PI3K (Phosphoinositide 3-Kinase) inhibitor space has evolved from a broad-spectrum, pan-isoform approach toward precision isoform-selective targeting, with PI3Kα (oncology/solid tumors) and PI3Kδ (hematologic malignancies) as the two dominant clinical axes. As of April 2026, 10 drugs have received regulatory approval across multiple isoforms and indications. The most active frontier is next-generation mutant-selective PI3Kα inhibitors — drawing major acquisition interest from Roche, Lilly, and Novartis — while the PI3Kδ hematology segment is maturing with Chinese domestic approvals. The competitive intensity…
This competitive landscape analysis was generated using AI-powered research workflows in Eureka LS, which integrates patent data, literature, and molecular insights into a structured report in minutes. Executive Summary The global obesity drug market is undergoing its most consequential transformation since the GLP-1 class emerged. Two Tier 1 leaders — Eli Lilly and Novo Nordisk — hold commanding positions with approved GLP-1 and dual-agonist assets generating blockbuster revenues, while racing each other on next-generation multi-agonists and oral formulations. Lilly gained a perceived competitive edge in 2025 when Zepbound (tirzepatide) overtook Wegovy (semaglutide) in US prescriptions, and orforglipron became the first oral small-molecule GLP-1R agonist approved…
This competitive landscape analysis was generated using AI-powered research workflows in Eureka LS, which integrates patent data, literature, and molecular insights into a structured report in minutes. Executive Summary The gene therapy sector has entered a commercial phase, with more than 15 approved products across AAV gene transfer, lentiviral cell-gene therapy, CRISPR/Cas9 editing, and oncolytic virus modalities. The competitive arena is moderately concentrated at the top (Sarepta, Novartis/AveXis, Vertex/CRISPR Therapeutics dominate commercially), but highly fragmented at the mid-tier — over 300 pipeline assets are in development as of 2025. A critical structural reset is underway: Vertex, Pfizer, Takeda, and Roche/Spark…
This competitive landscape analysis was generated using AI-powered research workflows in Eureka LS, which integrates patent data, literature, and molecular insights into a structured report in minutes. Executive Summary Breast cancer remains the world’s most diagnosed cancer in women, with 427 approved drugs across all subtypes and 506 active Phase 3 trials as of April 2026. Breast Cancer The competitive arena is highly stratified by molecular subtype — HR+/HER2−, HER2+, and TNBC — each with distinct treatment paradigms and player dynamics. Global leaders (Roche/Genentech, AstraZeneca, Pfizer, Eli Lilly, Daiichi Sankyo) dominate approved assets, while Chinese biotechs (Jiangsu Hengrui, Zymeworks, Kineta, Innovent, BeiGene) are aggressively challenging in…